Cramer was out with bullish comments tonight on Acadia Pharma (ACAD). Acadia makes drugs that treat antipsychotic conditions like schizophrenia and bipolar disorder. Interim results from phase II trials for ACP-103 are coming out soon as a treatment for Parkinson’s, he said, adding that more results are due out later in the year. Plus, Cramer said that ACP-104 has phase II results coming out later this year for its antipsychotic that he said is basically a better version of the widely used antipsychotic Clozapine. Cramer thinks if the trials go well the stock can go as high as $50, and on the flip side if the trials fail the stock could see $10. Cramer also feels that Sepracor (SEPR) which invests in Acadia may invest more if things go well.